News
US FDA approves Moderna’s Covid-19 vaccine, Spikevax in children aged 6 months through 11 years at increased risk for Covid-19 disease: Cambridge, Massachusetts Saturday, July 1 ...
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Zacks Investment Research on MSN20h
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key InsightsIn the latest close session, Moderna (MRNA) was down 1.87% at $33.64. This move lagged the S&P 500's daily loss of 0.33%. Meanwhile, the Dow lost 0.63%, and the Nasdaq, a tech-heavy index, lost 0.22%.
The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...
StockStory.org on MSN23h
U.S. Physical Therapy, Evolent Health, Charles River Laboratories, Moderna, and Intuitive Surgical Shares Are Falling, What You Need To KnowWhat Happened? A number of stocks fell in the morning session after the U.S. administration announced a sharp escalation in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback